Biogen

A Biogen facility in Cambridge, Massachusetts.Brian Snyder | ReutersBiogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category.Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. Revenue from multiple sclerosis products fell 8% to $1.17 billion as the therapies face…

Biogen is abandoning its lackluster Alzheimer’s disease drug, Aduhelm. The Massachusetts-based company announced Wednesday that it is pulling the medication from the market following poor sales and controversy over its approval by the Food and Drug Administration in 2021. The company says it is only doing so to “reprioritize” its resources toward its other, less contentious Alzheimer’s treatments, such as Leqembi.Lisa Frankenstein's Crew on Casting the Right Stars Adulhelm was developed by Biogen in conjunction with the…

The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023.Vanessa Leroy | Bloomberg | Getty ImagesBiogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer's drug Aduhelm to refocus the company's efforts to treat the memory-robbing disease. The biotech company will focus on rolling out Leqembi, a newly approved Alzheimer's drug it developed with Japanese drugmaker Eisai. It also plans to work on a slate of experimental treatments for the disease.…

The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you…

A Biogen facility in Cambridge, Massachusetts.Brian Snyder | ReutersBiogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved Alzheimer's drug Leqembi.It's the latest round of layoffs after Biogen slashed nearly 900 jobs last year. It had 8,725 employees worldwide as of the end of 2022.The job cuts are also part of the company's ongoing cost-cutting and reorganization plan, which also involves shaving down…

The biotech company cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products. The biotech company cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their…

On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive such approval and is intended to slow down the progression of the neurodegenerative disease.Will We See More of Uhura's Relationship with Spock? | io9 InterviewLeqembi is one of several antibody-based drugs that…

Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the…

The Food and Drug Administration on Thursday approved the Alzheimer's treatment Leqembi, a pivotal decision that is expected to expand access to the expensive drug for older Americans.Medicare has promised to start covering Leqembi, with some conditions, on the same day the FDA approves the antibody treatment. Leqembi is made by Japanese pharmaceutical company Eisai and its Cambridge, Massachusetts, partner, Biogen. Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval. It is also the first such…

Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients. Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the…